Search Results
Jan 12, 2026, 20:44 ET Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
Qiming Venture Partners and a leading global healthcare fund, with participation from a sovereign wealth fund, NGS Super (NGS), E-Town Capital, Elikon Venture, and Talon Capital. Proceeds will accelerate Oricell's global expansion and clinical development, while strengthening
More news about: OriCell Therapeutics Co., Ltd.
Jan 08, 2026, 10:30 ET Genomic Biomarkers Market worth $50.31 billion by 2030 | MarketsandMarkets™
next-generation sequencing (NGS) segment accounted for the largest share of the genomic biomarkers market.Next-generation sequencing (NGS) accounted for the largest share of the genomic biomarkers market in 2024. Hospitals, cancer centers, and pharma companies increasingly prefer NGS because a single
More news about: MarketsandMarkets
Jan 08, 2026, 08:00 ET Factorial Biotechnologies and Honeycomb Biotechnologies Partner to Deliver High-Throughput, Instrument-Free Single-Cell DNA Sequencing
sequencing, molecular biology, and bioinformatics. Factorial's in-cell library prep solution enables single-cell NGS libraries to be prepared at workflow and content parity with bulk NGS libraries, unlocking new discoveries and actionable insights. The company's Mosaic platform offers researchers accessible,
More news about: Factorial Biotechnologies
Jan 08, 2026, 03:30 ET STORM Therapeutics and AlidaBio Announce Strategic Collaboration to Accelerate Development of Cancer Therapies Targeting RNA Modifications
forefront of epitranscriptomics and RNA modification analysis. STORM will utilize AlidaBio's advanced EpiPlex® and EpiScout® next-generation sequencing (NGS) platforms to detect and quantitatively measure transcript-specific N6-methyladenosine (m6A) RNA modifications resulting from METTL3 inhibition. This
More news about: STORM Therapeutics
Jan 06, 2026, 09:00 ET BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East
investigators, broader clinical adoption of liquid biopsies in this setting required significantly higher sensitivity.Northstar Select's single-molecule NGS (smNGS) platform, powered by proprietary QCT™ technology, delivers ultrasensitive and precise quantification of DNA molecules—setting it apart from conventional
More news about: BillionToOne
Jan 06, 2026, 08:30 ET ePlus Appoints Mike Portegello to Board of Directors
HERNDON, Va., Jan. 6, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS – news) today announced that Mike Portegello, a global business
More news about: EPLUS INC.
Jan 05, 2026, 08:30 ET ePlus Technology Subsidiary Bailiwick Selected for Prestigious National Retail Federation Innovators Showcase For Digital Lock Technology
HERNDON, Va., Jan. 5, 2026 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Jan 05, 2026, 07:00 ET AerCap Leased, Purchased and Sold 705 Assets in the Full Year 2025 and 240 Assets in the Fourth Quarter 2025
helicopters.Completed 78 sale transactions for 62 aircraft (including 14 Airbus A320 Family aircraft, 3 Airbus A320neo Family aircraft, 4 Airbus A330s, 7 Boeing 737NGs, 2 Boeing 767-300ERs, 1 Boeing 777-200ER and 8 Embraer E195/E195-E2s from AerCap's owned aircraft portfolio and 23 aircraft from AerCap's managed aircraft
More news about: AerCap Holdings N.V.
Dec 30, 2025, 11:35 ET Sensiva Health names Donovan Blakney as Chief Operating Officer
molecular infectious disease diagnostics and infection control (SHIELD) to expanded precision medicine offerings, including next-generation sequencing (NGS), toxicology, pharmacogenomics (PGx) and genetic cancer testing, Donovan's leadership will support this growth. The company has also recently added a
More news about: Sensiva Health
Dec 22, 2025, 10:01 ET Next-generation Sequencing Services Market worth $8.77 billion by 2030 | MarketsandMarkets™
precision-medicine and genomics initiatives, and the dominant presence of the major NGS technology and service providers that work closely with hospitals, reference laboratories, and large population-health programs to stimulate NGS testing adoption.By application, the market is segmented into diagnostics,
More news about: MarketsandMarkets
Dec 19, 2025, 19:09 ET Das in Singapur ansässige Startup-Unternehmen Galatek sammelt 30 Millionen US-Dollar in einer Serie-A-Finanzierungsrunde ein, um die KI-gestützte Automatisierung in den Bereichen Biowissenschaften und Halbleiterfertigung voranzutreiben
die Forschungs-, Entwicklungs- und Service-Workflows hilft Galatek Wissenschaftlern, ihre Entdeckungen in komplexen Bereichen wie Diagnostik, NGS-Sequenzierung, 3D-Zell- und Organoidkultur, Arzneimittelentwicklung und synthetischer Biologie schneller voranzutreiben und Risiken zu minimieren. Das wird
More news about: Galatek
Dec 19, 2025, 13:07 ET Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
and Avida enrichment with Wasatch's novel sequencing technology and robust send-out service model, we are enabling customers to access high-quality NGS data without workflow barriers. This collaboration accelerates adoption, improves turnaround times, and provides a powerful, innovation-led path to achieving
More news about: Wasatch BioLabs
Dec 19, 2025, 08:06 ET Galatek, une startup basée à Singapour, lève 30 millions de dollars de série A pour accélérer l'automatisation basée sur l'IA dans les sciences de la vie et la fabrication de semi-conducteurs.
et de réduire les risques liés à la découverte dans des applications complexes, notamment les diagnostics, le séquençage de la prochaine génération (NGS), la culture de cellules et d'organoïdes en 3D, le développement de médicaments et la biologie synthétique. Ceci est encore renforcé par la plateforme
More news about: Galatek
Dec 16, 2025, 08:30 ET ePlus Vice President, Dori White, Named Solution Provider Marketing Executive of the Year in CRN's 2025 Women of the Year Awards
HERNDON, Va., Dec. 16, 2025 /PRNewswire/ -- ePlus inc. (NASDAQ NGS: PLUS –
More news about: EPLUS INC.
Dec 15, 2025, 16:40 ET BD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec
Raw Materials under the Alaset brand, Immunodiagnostics (Rapid Tests, Turbidimetry, and CLIA), and Molecular Biology (PCR and NGS) under the VIASURE brand as well as Pharma. Offering one of the widest portfolios in human in vitro diagnostics and pharma, the company builds
More news about: BD (Becton, Dickinson and Company)
Dec 15, 2025, 07:30 ET Pixelgen Technologies Further Expands Asia Presence Through Distribution Agreement with MDxK
protein abundance, clustering, and colocalization. The Pixelgen Proxiome Kit is instrument-free and easy-to-use, analogous to a sample-prep kit for NGS, and supports cells in suspension from PBMCs, BM, cell lines, and dissociated organoids.About Pixelgen TechnologiesPixelgen Technologies
More news about: Pixelgen Technologies
Dec 12, 2025, 10:15 ET AI Creation Engines Transform Biotech as Wellness Tech Captures Growth Wave
suite of SOPHiA DDM™ applications in oncology and rare disease, combining speed, scalability and flexibility to enable clinical researchers to transform NGS data into actionable insights within a single streamlined process."Integrating our universal platform with leading sequencing technologies such
More news about: Equity Insider
Dec 11, 2025, 13:06 ET Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China
localized testing approach helps reduce diagnostic costs, improve turnaround times, and expand access to high-quality NGS testing globally.The company offers more than 20 NGS testing kits in IVD or RUO formats, with multiple panels in various stages of development. Pillar Biosciences is headquartered
More news about: Pillar Biosciences, Inc.
Dec 11, 2025, 06:21 ET DNAe Unveils Early Access Program for LiDia‑SEQ™: Hospital Teams Invited to Trial DNAe's Flagship Tests and Preview DNAe's Innovative NGS Diagnostic Platform
preview the future of NGS diagnostics. We anticipate very strong interest from forward-thinking teams looking to evaluate game-changing, real‑world applications and accelerate the adoption of innovative solutions that will transform infection management worldwide."DNAe's rapid, NGS-based LiDia-SEQ™
More news about: DNAe
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
anti-BCMA and/or anti-GPRC5D therapies.Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=4).Potent and Sustained Pharmacodynamic Responses Observed with
More news about: Innovent Biologics
Dec 06, 2025, 08:30 ET Advances in Technology Help Improve Safety and Access to Blood Cancer Therapies
next-generation-sequencing (NGS) before starting the pre-transplant conditioning process. The trial met its primary endpoint with a two-year relapse-free survival rate comparable to that of an observational cohort of patients who received TBI-based conditioning."We used NGS-MRD – a very sensitive
More news about: American Society of Hematology
Dec 04, 2025, 08:30 ET Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium
Poster Session 1. December 10, 2025. 12:30-2:00 PM CSTComprehensive Characterization of PTEN loss by IHC and PTEN alteration by NGS in Metastatic HR-Positive, HER2-Negative Breast Cancer-- An Exploratory Analysis of Biomarker Concordance and Co-Occurrence. #PS2-08-02Poster
More news about: Caris Life Sciences
Dec 03, 2025, 12:00 ET ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting
treatments, design innovative clinical trials, and ultimately improve patient outcomes."ImpriMed will present data from a prospective study integrating NGS-based genomic profiling with ex vivo drug sensitivity testing across a panel of 21 drugs in AML patients treated with standard-of-care regimens. The
More news about: ImpriMed
Dec 02, 2025, 09:00 ET Ziwig Endotest®: Scientific Validation Published in NEJM Evidence
saliva-based diagnosisThe Ziwig Endotest® was evaluated through the analysis of 109 salivary microRNAs, combining next-generation sequencing (NGS) with artificial intelligence. Diagnostic interpretations were performed blindly, without prior knowledge of the patients' clinical status, ensuring
More news about: Ziwig
Dec 02, 2025, 04:31 ET Ziwig Endotest®: Wissenschaftliche Validierung veröffentlicht in NEJM Evidence
speichelbasierte DiagnoseDer Ziwig Endotest® wurde durch die Analyse von 109 microRNAs aus dem Speichel evaluiert, wobei Next-Generation Sequencing (NGS) mit künstlicher Intelligenz kombiniert wurde. Die diagnostische Auswertung erfolgte blind, d. h. ohne vorherige Kenntnis des klinischen Zustands der
More news about: Ziwig